Arbutus Biopharma Corporation investor relations material

Arbutus Biopharma Corporation is a biopharmaceutical company, which focuses on the development of novel therapeutics for chronic hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. The Company’s lead product candidate, ABT-493 is a first-in-class treatment for chronic hepatitis B virus (HBV) infection. ABT-493 has been granted Qualified Infectious Disease Product (QIDP) designation by U.S. Food and Drug Administration (FDA). It distributes its products in US hospitals, children's hospitals, acute care hospitals, outpatient clinics, home health care agencies etc.